STOCKS TELEGRAPH

Tag: ABEO stock

  • Abeona Therapeutics Inc. (ABEO) Stock Dipped in Premarket Despite no Visible Reason.

    Abeona Therapeutics Inc. (ABEO) is a clinical-stage novel biotherapeutics company engaged in the development of gene and cell therapies for life-threatening disorders. The lead product candidate of the company in Phase 3 trials is EB-101 for the treatment of recessive dystrophic epidermolysis bullosa. ABO-102 and ABO-101 in Phase 1/2 clinical trials are used in treating Sanfilippo syndrome.

    The price of ABEO stock during the regular trading on February 7, 2022, was $0.26 with an increase of 3.10%. At last check in the premarket on February 8, 2022, the stock dipped by 2.55%.

    ABEO: Events and Happenings

    On December 22, 2021, ABEO issued a letter to its stockholders regarding the recap of the company’s achievement of different milestones in 2021. The letter also stated the steps which have placed the company on the course of a transformative 2022. On December 17, 2021, ABEO updated about the pricing of a definite public offering of 44,700,000 shares of the company’s common stock and warrants for the purchase of 44,700,000 shares of common stock at a public offering price of $0.39 per share. The net profit from the offering was $17.5 million.

    On November 17, 2021, ABEO informed that its research data regarding ABO-102 was presented at the 14th Virtual International Congress of Inborn Errors of Metabolism on November 21-23, 2021.

    ABEO: Key Financials

    On November 15, 2021, ABEO released its financial results for the third fiscal quarter of 2021 ended September 30, 2021. Some of the main updates are mentioned below.

    Revenue

    The revenue in Q3 2021 was nil compared to the $7 million revenue in the same period of 2020. The analysts also expected no revenue in the quarter.

    EPS

    Basic and diluted net loss per share in Q3 2021 was $7.0 million or $0.07 compared to $7.2 million, or $0.08 in the same period of 2020. The company’s EPS beat the estimated figures by $0.02.

    Conclusion

    ABEO stock is 92% down the previous year due to pandemic recession. The company’s stock dipped in Tuesday’s premarket due to uncertain factors as there is no official press release or latest SEC filing available from the company. As the earnings release date of the quarter is near, the analysts are estimating the company’s EPS to be -$0.16.

  • Abeona Therapeutics Inc. (ABEO) stock Continues to Rise Premarket. Any Reason?

    On February 2, Abeona Therapeutics Inc. (ABEO) stock had increased by a further 7.14% premarket, at the last check. There is no official announcement or SEC filing from the company.

    In the previous trading session, the stock fluctuated between a high of $0.2840 and a low of $0.2571. ABEO closed the session at $0.2800 with a gain of 9.72% at a volume of 3.45 million shares. The stock has continued its bullish momentum so far, reaching up to $0.30 premarket, at the time of writing.

    The clinical-stage biopharmaceutical company, Abeona Therapeutics Inc. has a market capitalization of $37.42 million. Currently, the company has 101.92 million shares outstanding in the market.

    ABEO Stock Movement

    While there is no official announcement or SEC filing, the stock has been bullish since January 31, 2022. Moreover, the company doesn’t have any upcoming events scheduled either. It seems like the stock is gaining on external factors like social media chatter or stock sentiment. Given the bullish momentum of the stock, ABEO has added 16.72% in the past five days.

    In the bigger picture, ABEO stands at a year-to-date loss of 16.91% while it subtracted a huge 88.03% last year.

    Letter to Shareholders

    On December 22, the company issued a letter to its shareholders providing business highlights of 2021.

    The major highlights of 2021 as per the letter include:

    EB-101

    Nearly completed patient enrollment for Phase 3 VIITAL study of EB-101 in recessive dystrophic epidermolysis bullosa.

    Topline data from the trial is expected in Q3 of 2022.

    Preparation of cGMP commercial facility in Cleveland, Ohio.

    ABO-102

    Successful completion of Type B meeting with FDA for clarity on the regulatory path for ABO-102 in Sanfilippo syndrome type A (MPS IIIA).

    Six GMP lots of ABO-102 were manufactured.

    Commenced construction of commercial AAV facility at Cleveland site.

    ABO-101

    Closed enrollment in Transpher B study of ABO-101 in Sanfilippo syndrome type B (MPS IIIB).

    Additionally, ABEO is also planning to work on common diseases with its preclinical programs evaluating novel AAV capsids in 5 undisclosed ophthalmic conditions.

    ABEO’s Financial Overview

    In the third quarter of 2021, the company had a net loss of $7 million, against $7.2 million in Q3 2020. Therefore, the net loss per basic and diluted share was $0.07 and $0.08 in Q3 of 2021 and 2020, respectively.

    ABEO ended the quarter with cash, cash equivalents, and short-term investments of $67 million on September 30, 2021.

  • Abeona Therapeutics Inc. (ABEO) stock Plunges Deep in the After Hours. Reasons?

    On December 16, Abeona Therapeutics Inc. (ABEO) stock plunged by a further 22.15% in the after-hours on news of a public offering. The stock was already in the red but the news caused it to fall further deep.

    During regular trading, the stock was down by 6.39% at the closing price of $0.4881 on Thursday. Following the news, the stock fell down to $0.3800 in the after-hours at 2.77 million shares.

    Currently, the 101.92 million outstanding shares of the biopharma trade at a market capitalization of $53.14 million.

    ABEO’s Public Offering

    On Thursday, the company announced a public offering of its common stock and warrants. As per the underwritten offering, the company will sell shares of its common stock along with the warrant for its purchase. Moreover, the offer will be made pursuant to an existing shelf registration statement.

    Further, the size, terms, and closing which are subject to market condition, were not disclosed. In addition, the sole book-running manager for the offering is Cantor Fitzgerald and Co. And the lead manager for the offering is A.G.P/Alliance Global Partners.

    The net proceeds of the offering are intended for the continued funding of pipeline products as well as corporate purposes.

    Support of EB Research Partnership

    Previously the company sponsored the second annual Venture Into Cures, which was held virtually on November 18. It is a virtual event that supports the mission of the EB Research Partnership. Moreover, EB Research Partnership has been trying to find a cure for EB (epidermolysis bullosa) which is a connective tissue disorder with severe skin wounds.

    ABEO is currently working on EB-101 as a treatment for patients with the most severe form of EB. Furthermore, in collaboration with Stanford University Medical Center and UMass Memorial Medical Center, Phase 3 VITALTM study is being advanced.

    ABEO’s Financial Analysis

    On November 15, ABEO announced its financial results for the third quarter of 2021. In the third quarter of 2021, the company had no revenues while a year ago it had $7.0 million. The previous year’s revenue was generated from sublicense and inventory purchase agreements of ABO-202.

    Moreover, in the third quarter of 2021, the R&D and G&A expenses were $8.0 million and $6.1 million, respectively. This compares to $8.0 million and $4.4 million in the year-ago period.

    Further, the third quarter saw a net loss of $7.0 million, against $7.2 million in the Q3 of 2020. Consequently, the net loss per basic and diluted share was $0.07 and $0.08 in the Q3 of 2021 and 2020, respectively.

  • Abeona Therapeutics, Inc. (ABEO) Stock Relatively Stable Following Positive Data for Sanfilippo Syndrome Treatment

    Abeona Therapeutics, Inc. (ABEO) stock prices were up 0.76% as of the market close on July 26th, 2021, bringing the price per share up to USD$1.32 at the end of the trading day. Subsequent current market fluctuations saw the stock fall by 5.30%, bringing it down to USD$1.25.

    Promising Topline Data

    July 26th, 2021 saw ABEO stock announce magnetic resonance imaging (MRI) data from the Phase 1/2 Transpher A clinical study. The study indicated that ABO-102 increases grey matter, corpus callosum, and amygdala volumes in the brain. The study consisted of three young patients with Sanfilippo Syndrome Type A (MPS IIIA) at 24 months, compared to afflicted patients who did not receive treatment. The findings were presented by ABEO stock during an oral presentation at the 16th International Symposium on MPS and Related Diseases.

    Scope of Findings

    Brain volume loss is typical in children with MPS IIIA and is linked to long-term cognitive and physical disability. Grey matter has been found to be important for cognitive development, whereas the corpus callosum is crucial for motor function. The amygdala plays a critical role in fear learning as well as social/emotional development. The findings highlight the potential of ABO-102 to increase brain grey matter, corpus callosum, and amygdala volumes. This potential is in line with ABEO stocks’ previously reported results of preservation of neurocognitive development in the three young patients in the Transpher A study.

    ABEO Stock’s Study Endpoints

    The Transpher A study primary endpoints targeted neurodevelopment and the treatment’s safety. Secondary endpoints include, but are not limited to, brain volume, behavior evaluations, quality of life, enzyme activity in cerebrospinal fluid (CSF) and plasma, heparan sulfate levels in CSF, plasma, and urine, and liver volume.

    About the Study

    The Transpher A Study is a two-year process that is currently ongoing as an open-label, dose-escalation, Phase 1/2 global clinical trial. It is designed to assess the treatment of patients with Sanfilippo syndrome type A (MPS IIIA) with the use of ABEO stock’s ABO-102. The study is known as ABT-001 and is intended for patients ranging from birth to 2 years of age, or for patients older than 2 years with a cognitive developmental quotient of 60% or above.

    Future Outlook for ABEO

    Armed with the latest data from its highly promising study, ABEO stock is poised to capitalize on the opportunities ahead of it. The company is keen to push for the accelerated development and proliferation of ABO-102, which investors hope will translate into long-term gains in shareholder value.

  • What changed for these 49 stocks in Pre-Market Session?

    What changed for these 49 stocks in Pre-Market Session?

    Fuel Tech Inc. (FTEK) stock plunged -8.8% to $1.14 in the pre-market trading after the technology company offered advanced engineering solutions for the optimization of combustion, pollution control, and water treatment systems in utility and industrial applications, financial results for the third quarter were officially published. The most recent rating by H.C. Wainwright, on March 13, 2020, is at a Neutral.

    Equillium Inc. (NASDAQ: EQ) shares are trading down -4.17% at $4.83 at the time of writing after on November 11, the company announced quarterly results for the third quarter of 2020. The company’s 52-week range was noted as $2.20 to $27.05. Analysts have a consensus price target of $24.

    Immuron Limited (IMRN) tumbled over -4.17% at $8.05 in pre-market trading today. US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine.

    Infinity Pharmaceuticals Inc. (INFI), a Biotechnology company, dropped about -6.62% at $1.41 in pre-market trading Thursday following an earnings surprise of -6.67 percent was revealed by the company. It was anticipated a quarter ago that this drugmaker would report a loss of $0.20 per share when it actually posted a $0.16 loss, providing a 20 percent surprise.
    .

    Tellurian Inc. (TELL) stock moved down -5.6 percent to $1.18 in the pre-market trading following the company finished the third quarter of 2020, with cash and cash equivalents of roughly $77.9 million and current borrowings of about $80.8 million. The balance sheet of Tellurian accounted for about $293.3 million in total assets.

    Co-Diagnostics Inc. (CODX) gained over 5.19% at $13.99 in pre-market trading Thursday 12 November 2020. Co-Diagnostics, Inc. CoPrimers™ Shown to be Effective in COVID-19 Saliva PCR Tests Without Sample Extraction.

    Abeona Therapeutics Inc. (ABEO) is down more than -3.85% at $1.25 in pre-market hours Thursday 12 November 2020 after a front-runner in gene and cell therapy, revealed quarterly results and business updates. The stock had jumped over 13.04% to $1.30 in the last trading session.

    Before the trading started on 12 November 2020, MannKind Corporation (MNKD) is down -3.57% to reach $2.7. It has been trading in a 52-week range of $0.80 to $2.52.

    RAVE Restaurant Group Inc. (RAVE) stock plunged -11.84% to $0.67 in the pre-market trading. The most recent rating by ROTH Capital, on May 12, 2016, is at a Neutral.

    Dada Nexus Limited (NASDAQ: DADA) shares are trading up 5.08% at $32.7 at the time of writing. The company’s 52-week range was noted as $14.60 to $37.38. Analysts have a consensus price target of $36.

    FuelCell Energy Inc. (FCEL) tumbled over -1.49% at $2.65 in pre-market trading today.

    Zoom Video Communications Inc. (ZM), a Telecom Services company, rose about 3.38% at $427.3 in pre-market trading Thursday.

    Canaan Inc. (CAN) stock moved up 3.05 percent to $2.7 in the pre-market trading.

    Muscle Maker Inc. (GRIL) lost over -9.6% at $1.79 in pre-market trading Thursday 12 November 2020.

    Moderna Inc. (MRNA) is up more than 5.03% at $86.59 in pre-market hours Thursday 12 November 2020. The stock had jumped over 8.40% to $82.44 in the last trading session. Moderna Has Completed Case Accrual for First Planned Interim Analysis of its mRNA Vaccine Against COVID-19 (mRNA-1273).

    Before the trading started on 12 November 2020, Coty Inc. (COTY) is down -3.89% to reach $4.45 after the company topped analysts’ outlook and surged as much as 22.2% on Nov 6 following its first-quarter fiscal 2021 results. It has been trading in a 52-week range of $2.65 to $13.01.

    Pinduoduo Inc. (PDD) stock soared 17.53% to $131.0 in the pre-market trading following an innovative and emerging tech firm and one of the top Chinese e-commerce players, revealed its unaudited financial results for the third quarter ended September 30, 2020. The most recent rating by Goldman, on November 03, 2020, is a Buy.

    Sea Limited (NYSE: SE) shares are trading up 3.48% at $175.01 at the time of writing following the news recently that pharmaceutical companies are closing on their COVID-19 vaccine candidates. The company’s 52-week range was noted as $30.50 to $187.75. Analysts have a consensus price target of $164.

    GrowGeneration Corp. (GRWG) grew over 7.26% at $22.46 in pre-market trading today after GrowGeneration reported record third-quarter 2020 Financial Results.

    Blink Charging Co. (BLNK), a Specialty Retail company, rose about 5.09% at $10.73 in pre-market trading Thursday.

    LightInTheBox Holding Co. Ltd. (LITB) stock moved up 3.31 percent to $2.5 in the pre-market trading.

    Bionano Genomics Inc. (BNGO) gained over 14.13% at $0.639 in pre-market trading Thursday 12 November 2020. Multi-Center Evaluation of Bionano Optical Genome Mapping by Cytogenetics Thought Leaders in the US Leads to Recommendation for Bionano’s Saphyr to Replace Karyotyping as First-Line Test for Detection and Identification of Structural and Copy Number Variants in Leukemia Patients.

    Vroom Inc. (VRM) is down more than -9.88% at $36.77 in pre-market hours Thursday 12 November 2020 following Vroom reported third Quarter 2020 results. The stock had jumped over 6.56% to $40.80 in the last trading session.

    Before the trading started on 12 November 2020, Turkcell Iletisim Hizmetleri A.S. (TKC) is up 3.16% to reach $5.23. It has been trading in a 52-week range of $4.36 to $6.36.

    Himax Technologies Inc. (HIMX) stock soared 12.2% to $4.6 in the pre-market trading after the prediction of Revenue to surge by approx. 10% consecutively and Gross Margin to get close to 29%. The most recent rating by Credit Suisse, on April 01, 2020, is at an Outperform.

    Qualigen Therapeutics Inc. (NASDAQ: QLGN) shares are trading down -10.03% at $3.23 at the time of writing. The company’s 52-week range was noted as $3.29 to $21.50.

    NovaBay Pharmaceuticals Inc. (NBY) grew over 8.82% at $0.67 in pre-market trading today.

    IMAC Holdings Inc. (IMAC), a Medical Care Facilities company, rose about 146.1% at $2.05 in pre-market trading Thursday. IMAC Holdings, Inc. Expands Missouri Footprint with Acquisition of Lockwood Chiropractic in Webster Groves.

    Sino-Global Shipping America Ltd. (SINO) stock moved up 62.18 percent to $3.13 in the pre-market trading.

    InVivo Therapeutics Holdings Corp. (NVIV) lost over -3.21% at $0.555 in pre-market trading Thursday 12 November 2020.

    Castor Maritime Inc. (CTRM) is up more than 18.5% at $0.1595 in pre-market hours Thursday 12 November 2020 after the company posted fiscal Results for the Three Months and Nine Months Ended September 30, 2020. The stock had jumped over 4.95% to $0.13 in the last trading session.

    Before the trading started on 12 November 2020, Just Energy Group Inc. (JE) is down -13.28% to reach $5.29 as a retail energy provider specializing in electricity and natural gas commodities, revealed its quarterly results for the fiscal year 2021. It has been trading in a 52-week range of $4.27 to $93.72.

    OraSure Technologies Inc. (OSUR) stock soared 4.55% to $14.02 in pre-market trading after the company recently topped its 3rd quarter fiscal earnings predictions. The most recent rating by Evercore ISI, on August 21, 2020, is at an Outperform.

    Riot Blockchain Inc. (NASDAQ: RIOT) shares are trading up 4.17% at $3.75 at the time of writing after the news that Bitcoin might take off again after a big gap. The company’s 52-week range was noted as $0.51 to $4.58.

    NortonLifeLock Inc. (NLOK) tumbled over -7.02% at $18.68 in pre-market trading today despite the earnings beat in the recent week.

    NIO Limited (NIO), an Auto Manufacturers company, rose about 3.41% at $44.55 in pre-market trading Thursday after the analyst’s prediction that NIO can be the main player in the Electric Vehicle market.

    JD.com Inc. (JD) stock moved up 5.38 percent to $87.3 in the pre-market trading following the news that JD.com was the largest US seller in China on Singles day.

    Kandi Technologies Group Inc. (KNDI) gained over 8.84% at $6.77 in pre-market trading Thursday 12 November 2020 despite its disappointing sales results in the financial 3rd quarter of this year.

    ICL Group Ltd (ICL) is up more than 3.11% at $3.98 in pre-market hours Thursday 12 November 2020 as the company topped analysts’ outlook on every front. The stock had jumped over 3.21% to $3.86 in the last trading session.

    Before the trading started on 12 November 2020, Uxin Limited (UXIN) is down -3.81% to reach $1.01 after the news that the company’s proprietary rating system has been introduced that assesses and determines the quality of a used vehicle, offers greater precision to make the decision-making process simpler for consumers and enhances the overall consumer experience. The stock has been trading in a 52-week range of $0.72 to $3.30.

    Baozun Inc. (BZUN) stock soared 3.07% to $40.57 in pre-market trading after the news that the stock still carries a great potential for investors. The most recent rating by Credit Suisse, on June 03, 2020, is at an Outperform.

    XpresSpa Group Inc. (NASDAQ: XSPA) shares are trading up 4.47% at $1.87 at the time of writing after the news that the firm to offer Business Update and will reveal Third Quarter 2020 Financial Results on November 16, 2020. The company’s 52-week range was noted as $0.15 to $8.82.

    KE Holdings Inc. (BEKE) grew over 3.48% at $72.02 in pre-market trading today after the news that the company will announce its quarterly report on November 16, 2020.

    Revolve Group Inc. (RVLV), an Internet Retail company, dropped about -8.96% at $20.43 in pre-market trading Thursday after the company Announced Third Quarter 2020 Financial Results with topping all analysts predictions.
    .

    American Tower Corporation (REIT) (AMT) stock moved up 2.75 percent to $245.0 in the pre-market trading after the reports that the company took over InSite Wireless Group for USD 3.5 billion.

    BIO-key International Inc. (BKYI) gained over 16.2% at $0.52 in pre-market trading Thursday 12 November 2020.

    Liminal BioSciences Inc. (LMNL) is up more than 11.19% at $4.57 in pre-market hours Thursday 12 November 2020 after the report that the firm will reschedule its announcement of quarterly results and conference call. The stock had jumped over 2.49% to $4.11 in the last trading session.

    Before the trading started on 12 November 2020, GoHealth Inc. (GOCO) is down -4.5% to reach $12.73. It has been trading in a 52-week range of $10.02 to $26.25.

    XPeng Inc. (XPEV) stock soared 10.53% to $37.06 in pre-market trading after the company unveiled upbeat quarterly results. The most recent rating by Citigroup, on November 04, 2020, is a Buy.